← Eichor
Study identifier: NCT05660460 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

COPD at a Street Level

Condition: COPD  ·  Sponsor: Hvidovre University Hospital

PhaseNA
Planned participants511
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersYes

About this study

The trial investigates and describes the prevalence of COPD among socially vulnerable individuals who come in contact with a mobile clinic and investigates the effect of opportunistic screening for COPD in these vulnerable persons. The study population is individuals who come in contact with a mobile clinic, that visits home shelters, open drugs scenes etc. in the Capital Region of Denmark during the inclusion period, and monitor them for up to 1 year in order to investigate variables that are significant in terms of the patients' treatment, hospitalizations, and mortality in relation to COPD. Our hypothesis is that there will be a higher incidence of COPD among socially vulnerable individuals who come in contact with the mobile clinic than in the general population.

This description comes directly from the study's public registry record.

Talk to the study team

Jannet van der Veen  ·  +45 21157392  ·  jannet@brugernesakademi.dk

Mette Lindstroem, MPH  ·  +45 38623308  ·  mette.bendtz.lindstroem@regionh.dk

Always discuss trial participation with your own doctor first.

Locations (1)

Brugernes AkademiCopenhagen, DenmarkRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05660460